NCT01036438

Brief Summary

Compare the efficacy of using an absorbent foam silver dressing (Mepilex Ag) versus the equivalent dressing without silver in subjects suffering from venous leg ulcer or mixed ulcer with an ABPI ≥ 0.8 and with inflammatory signs. Efficacy will be defined as absolute wound size reduction.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
201

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Dec 2009

Longer than P75 for phase_4

Geographic Reach
4 countries

44 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2009

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

December 18, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 21, 2009

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2013

Completed
12 months until next milestone

Results Posted

Study results publicly available

September 12, 2014

Completed
Last Updated

September 12, 2014

Status Verified

December 1, 2013

Enrollment Period

3.8 years

First QC Date

December 18, 2009

Results QC Date

September 4, 2014

Last Update Submit

September 11, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • Efficacy Will be Defined as Absolute Wound Size Reduction.

    Efficacy will be defined as absolute wound size reduction.

    8 weeks

Secondary Outcomes (1)

  • Change in Inflammatory Signs

    4 weeks

Study Arms (2)

Mepilex product

PLACEBO COMPARATOR
Device: Mepilex without Ag

Mepilex Ag

ACTIVE COMPARATOR
Device: Mepilex Ag

Interventions

Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.

Mepilex Ag

Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.

Mepilex product

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects with colonised/ local infection in a venous leg ulcer or mixed leg ulcer with an ABPI ≥ 0,8 and \< 1.3
  • A history of an appropriate compression therapy for at least 2 weeks prior to randomisation
  • Subjects with colonised/local infection presenting with three of five following specified signs:
  • pain between dressing changes
  • exuding wounds
  • erythema on peri-wound skin
  • oedema
  • odour
  • An ulcer size of at least 4 cm2 and a maximum size witch could be covered by one investigational product of 15x15 cm.
  • Ulcer duration 6 weeks to 1 year
  • In case of multiple ulcers: target ulcer must be at least 3 cm distant from other ulcers.
  • Both gender with an age ≥ 18 years
  • Signed informed consent

You may not qualify if:

  • \> 10% necrotic (black) or fibrinous (yellow) tissue covering the wound bed
  • Infected wounds in need of systemic antibiotic treatment
  • Previous treatment with MepilexAg® on the target ulcer
  • Use of systemic antibiotics for any reason during the previous 7 days
  • Diagnosed underlying disease(s) (e.g. HIV/AIDS, cancer/malignancy and severe anaemia) judged by the investigator to be a potential interference in the wound evaluation
  • Subjects with poorly controlled diabetes mellitus i.e. HbA1c \>8%
  • Subjects treated with systemic immunosuppressive or glucocorticosteroids, except subjects taking occasional doses or doses less than 10mg prednisolon/day or equivalent. Subjects inhaling glucocorticosteroids for asthma should not be excluded.
  • Known allergy/hypersensitivity to any of the components of the investigation products.
  • Subjects with physical and/or mental conditions that are not expected to comply with the investigation due to poor medical condition
  • Participation in other clinical investigation(s) within 1 month prior to start of the investigation.
  • Previously randomised to this investigation.
  • Life expectance of the subject less than 3 months
  • Pregnant or breast-feeding women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (44)

Nemocnice Jihlava

Jihlava, Jihlava, 586 01, Czechia

Location

Krajská nemocnice Liberec

Liberec, Liberec, 46063, Czechia

Location

chirugické oddělení, Fakultní nemocnice Královské Vinohrady

Prague, Prague, 10 PSČ 100 34, Czechia

Location

Nemocnice Podlesí a.s.

Třinec, Třinec, 73961, Czechia

Location

Uherskohradišťská nemocnice a. s.

Uherské Hradiště, Uherské Hradiště, 68668, Czechia

Location

Fakultní nemocnice U svate Anny, St. Anne´s University Hospital

Brno, 65691, Czechia

Location

Dermatovenerologická klinika, University Hospital Bohunice,

Brno, Czechia

Location

Dermatovenerologická klinike, Univerzita Karlova

Pilsen, 305 99, Czechia

Location

Fakultní nemocnice Na Bulovce

Prague, 180 00, Czechia

Location

Masarykova Hospital, Dermatology dept.

Ústí nad Labem, 401 13, Czechia

Location

Dermatovenerologie Rendlová s.r.o.

České Budějovice, České Budějovice, 37001, Czechia

Location

Polyclinique de Picardie Service d'Angiologie Phlébologie

Amiens, Amiens, 80000, France

Location

Hôpital privé d'Antony Service de Dermatologie

Antony, Antony, 92160, France

Location

Hôpital Saint Jacques - CHU Besançon

Besançon, Besançon, 25030, France

Location

Résidence le Bristol

Boulogne-sur-Mer, Boulogne-sur-mer, 62200, France

Location

CHU Le Bocage Service Dermatologie

Dijon, Dijon Cedex, 21079, France

Location

Hôpital Albert Michallon Service de médecine vasculaire

Grenoble, Grenoble Cedex 9, 38 043, France

Location

CHG La Roche-sur-Yon Service de D'Angiologie,Les Oudairies

La Roche-sur-Yon, La Roche-sur-Yon, 85925, France

Location

Centre Hospitalier le Mans Service de Dermatologie

Le Mans, Le Mans Cedex 9, 72037, France

Location

Pharmacie Centrale-Service Arsenal

Nantes, Nantes, 44093, France

Location

APHP Hôpital Lariboisère

Paris, Paris, 75010, France

Location

Hôpital Saint Joseph

Paris, Paris, 75014, France

Location

Cabinet d'Angiologie, 1 bis rue de Salgareda

Saint-Alban, Saint Alban, 31140, France

Location

Dermatology Department, University Hospital, Hopital Sud

Amiens, 80054, France

Location

Service de Dermatologie, Centre Hospitalier Regional Universitaire

Caen, 140 33, France

Location

Cabinet D'Angeiologie

Lille, 690 00, France

Location

Hopital Maringer-Villemin- Fournier

Nancy, France

Location

Hôpital Rotchild - Jean Rostand

Paris, 75012, France

Location

Hopital Robert Debré Service de Dermatologie

Reims, France

Location

Hopital Charles Nicolle

Rouen, France

Location

Maison de Santé Protestante de Bordeaux-Bagatelle

Talence, France

Location

Hopital Beauregard / Secrétariat de Dermatologie

Thionville, 57100, France

Location

Service de dermatologie

Toulon, France

Location

Clinique Pasteur

Toulouse, 31076, France

Location

Universitätsklinikum Schleswig-Holstein Campus Lübeck

Lübeck, Germany, 23538, Germany

Location

Universtätsmedizin Charité Klinik für Dermatologie, Allergologie und Venerologie

Berlin, 10117, Germany

Location

Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken -

Bochum, 44805, Germany

Location

Universitätsklinikum Hamburg-Eppedorf

Hamburg, 20246, Germany

Location

Bramfelder Chaussee 200

Hamburg, 22177, Germany

Location

Universität klinikum Jena, Klinik für dermatologie und dermatologische

Jena, 07740, Germany

Location

University Hospital Regensburg

Regensburg, Germany

Location

Universitäts-Hautklinik

Tübingen, 72076, Germany

Location

Dermatology department

Amsterdam, 1081, Netherlands

Location

St. Antonius Ziekenhuis

Utrecht, Netherlands

Location

Results Point of Contact

Title
Ann Larkö
Organization
Molnlycke Health Care AB

Study Officials

  • Sylvie Meaume, Dr

    Hopital Rotchild - Jean Rostand, Paris

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 18, 2009

First Posted

December 21, 2009

Study Start

December 1, 2009

Primary Completion

October 1, 2013

Study Completion

October 1, 2013

Last Updated

September 12, 2014

Results First Posted

September 12, 2014

Record last verified: 2013-12

Locations